logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug Ifenprodil.

Algernon shared details about that study and he also takes a broader look at the drug Ifenprodil and the number of studies they are undertaking to see it’s effectiveness in treating respiratory conditions

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.34 CAD

CSE:AGN
Market: CSE
Market Cap: $37.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Algernon Pharmaceuticals' drug identified by University of Texas as possible...

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) CEO Christopher Moreau tells Proactive an independent research study by the University of Texas at Dallas has identified its drug Ifenprodil as one of several possible drug candidates to treat the coronavirus disease. Moreau, who will be...

2 weeks ago

2 min read